Phase II
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
Pfizer says it expects the U.S. CDC’s ACI to meet in October to recommend the appropriate and safe use of pneumococcal vaccines, including PREVNAR 20, in adults.
Indivior PLC is collaborating with France-based Aelis Farma on the development of a treatment for cannabis use disorder and cannabis-induced psychosis.
The FDA lifted the clinical holds on bluebird bio’s sickle gene therapy and its betibeglogene autotemcel gene therapy for adults, adolescents and children with TDT.
With the 2021 American Society of Clinical Oncology meeting held late last week, there is plenty of clinical trial news.
Shares of Protagonist Therapeutics climbed nearly 4% in premarket trading after the company announced its lead drug candidate rusfertide snagged Breakthrough Therapy Designation from the U.S. FDA.
Sanofi’s experimental breast cancer treatment amcenestrant in combination with Pfizer’s Ibrance is showing promising anti-tumor activity in postmenopausal women with metastatic breast cancer.
BioSpace continues to take a look at some of the data that will be shared at the 2021 ASCO meeting. Here are some of them.
MorphoSys Pharma is acquiring Constellation Pharmaceuticals for about $1.7 billion. Here’s everything you need to know about this billion dollars deal.
Inclusions and treatment initiation will be paused in all ongoing clinical studies until an investigation into the potential safety issue is complete.
PRESS RELEASES